A Phase 2 study of E7777 in patients with relapsed or refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223116

Enrollment

Registered

2016-02-26

Start date

2016-03-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The patients with relapsed or refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma

Interventions

investigational material(s) Generic name etc : E7777 INN of investigational material : - Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material :

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Participants who have histological diagnosis as peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL). 2.Participant who have measurable disease. 3.Participant who had previous systemic chemotherapy. 4.Participant who had disease progression (PD) or did not have response (complete response (CR) or partial response (PR)) in systemic chemotherapy, or relapsed or progressed after systemic chemotherapy. 5.Participant with Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1. 6.Participant with adequate renal, liver and bone marrow function. 7.Male and female participants ≥20 years of age at the time of informed consent. 8.Participants who have provided written consent to participate in the study.

Exclusion criteria

Exclusion criteria: 1.Participant with serious complications or histories. 2.Participant with history of hypersensitivity to protein therapeutics. 3.Participant who is positive for Human immunodeficiency virus (HIV) antibody, Hepatitis C virus (HCV) antibody, or Hepatitis B Surface (HBs) antigen. 4.Participant with malignancy of activity other than PTCL or CTCL within 36 months before informed consent. 5.Women of childbearing potential or man of impregnate potential who don't agree to use a medically effective method for contraception. 6.Woman who is pregnant or lactating. 7.Participant with allogeneic stem cell transplantation. 8.Participant who were decided as inappropriate to participate in the study by the investigator or sub-investigator.

Design outcomes

Primary

Measure	Time frame
efficacy Objective Response Rate (ORR)	—

Secondary

Measure	Time frame
efficacy -	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026